[The effect of metformin on late diabetic complications and cardiovascular events in obese patients with type 2 diabetes].
The aim of this review, after a short presentation of the United Kingdom Prospective Diabetes Study (UKPDS), is to stress that metformin is the drug of choice for overweight type 2 diabetic patients. The effect of metformin on various cardiovascular risk factors is briefly discussed.
Christiansen
Allan Lindskov
AL
H:S Hvidovre Hospital, medicinsk endokrinologisk afdeling.
Madsbad
Sten
S
D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D048909:Diabetes Complications; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D003925:Diabetic Angiopathies / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D008687:Metformin / Q000008:administration & dosage*; D009765:Obesity; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013997:Time Factors
D007004:Hypoglycemic Agents; D008687:Metformin